South San Francisco, California, United States, November 2025 — Kristina Cutter has been elevated to the role of Chief Development Officer (CDO) at Alector, marking a significant step in her long-standing leadership journey in regulatory affairs, pharmacovigilance and quality. Building on years of impact within the organization, she now guides Alector’s development strategy for its neuroscience and neurodegeneration pipeline.
In her most recent role as Chief Regulatory, Pharmacovigilance & Quality Officer at Alector, held for nearly seven years, Kristina led multi-disciplinary teams driving regulatory strategy, safety operations and quality frameworks. Her leadership supported the advancement of Alector’s innovative programs targeting neurodegenerative diseases.
Before that, she served as Senior Vice President, Regulatory Affairs, Pharmacovigilance & Quality Assurance, and earlier as Vice President, Regulatory Affairs and Pharmacovigilance at Alector. Across these roles, totaling several years, she supported the progression of Alector’s scientific programs and strengthened regulatory pathways critical to the company’s mission.
Prior to joining Alector, Kristina held multiple senior roles at Halozyme Therapeutics, including Vice President and Head of Regulatory Affairs and Operations, where she spent more than four years shaping regulatory and safety operations. She previously served as VP Regulatory & Safety at DIA, building foundational leadership experience in regulatory and safety functions.
Earlier in her career, Kristina held leadership positions across prominent global biopharma companies, including Senior Director, Franchise Head of Global Regulatory Affairs at Roche, Executive Director and Director roles at Amgen, and senior regulatory roles at InterMune Inc. and Pfizer Inc. Her experience spans commercial regulatory oversight, global pipeline strategy, regulatory promotion, and cross-functional leadership across ophthalmology, respiratory, oncology and immunology portfolios.
About Alector
Alector is a late-stage clinical biotechnology company dedicated to making degenerative brain disorders history. Focused on high unmet medical needs in neurodegeneration, Alector develops therapeutic candidates designed to counteract disease progression by removing toxic proteins, restoring deficient proteins and repairing dysfunctional immune and neuronal pathways. Leveraging genetically validated targets, proprietary protein engineering capabilities, antibody discovery expertise and its innovative Alector Brain Carrier (ABC) platform for efficient blood-brain barrier transport, Alector advances a diverse pipeline engineered to transform the future of neuroscience. Founded in 2013, the company is headquartered in South San Francisco, California.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
